Posted by Chairman_MAO on February 21, 2007, at 14:17:13
In reply to Re: willyee: trouble with parnate » willyee, posted by Quintal on February 18, 2007, at 0:51:51
Many people do have success with Parnate alone. The problem is that it's given in inadequate doses. The dosage range at which it is really effective is 120-200mg/day, not 30-60mg/day. However, those with significant (non-phobic) anxiety in addition to whatever else often find it too stimulating. It is worthy of mention, though, that the side effects usually DECREASE once you hit around 1.5mg/kg.
Personally, I hated the up-down psychostimulant effect that made me need to take it every 3 hours.
Taking Nardil with Dexedrine is much better for me.1: Pharmacopsychiatry. 1989 Jan;22(1):21-5.
High dose tranylcypromine therapy for refractory depression.
Amsterdam JD, Berwish NJ.
Department of Psychiatry, School of Medicine, University of Pennsylvania,
Philadelphia.A substantial number of depressed patients will experience a chronic,
treatment-resistant affective disorder. Aggressive treatment of these patients
with various drug combinations, unconventional antidepressants, or
electroconvulsive therapy has met with only partial success. There remains a
pressing need to identify more effective methods of utilizing "first-line"
antidepressant agents to achieve a more rapid therapeutic action. To this end,
we initiated a study using high doses of the MAO inhibitor tranylcypromine, at a
range of 90 mg to 170 mg daily, in seven refractory depressed patients who had
failed to respond to at least three prior treatments regimens. Four out of seven
subjects (57%), who had failed to respond to a mean of 8 +/- 5 prior treatment,
had a complete response, and one patient had a partial response to high dose
tranylcypromine. The mean SD maximum tranylcypromine dose for the responders was
112 +/- 16 mg daily (range 90 mg to 130 mg). Response did not appear to be a
function of severity of illness, duration of present episode, or the number of
prior treatment failures. Overall, the side effect profile was favorable, and no
"cheese reactions" were encountered. These observations are of clinical
significance and suggest the need for further controlled studies using high
doses of tranylcypromine.1: Neurochem Res. 1994 Jan;19(1):5-8.
Effects of low- and high-dose tranylcypromine on [3H]tryptamine binding sites in
the rat hippocampus and striatum.Goodnough DB, Baker GB, Mousseau DD, Greenshaw AJ, Dewhurst WG.
Department of Psychiatry, University of Alberta, Edmonton, Canada.
Chronic studies were initiated in rats to determine the effects of high- and
low-dose tranylcypromine (TCP) on [3H]tryptamine (3H-T) binding sites. Male
Sprague-Dawley rats were administered TCP (0.5 or 2.5 mg/kg/day) or vehicle
(distilled water) for 4, 10 or 28 days via Alzet minipumps. After decapitation,
the hippocampus and striatum were used to prepare membrane fragments for single
point 3H-T binding. Hippocampal 3H-T binding was reduced after 10 and 28 days
with the low dose and after 4, 10 and 28 days with the high dose. Striatal 3H-T
binding was reduced by both doses at all time intervals. The high dose resulted
in a significantly greater reduction in striatal 3H-T binding than did the
low-dose after 4, 10, and 28 days. These results suggest that a more rapid
reduction of 3H-T binding in the hippocampus and/or a greater reduction of 3H-T
binding in the striatum by high-dose TCP than by low-dose TCP may be
contributing factors in the reported efficacy of the former in refractory
depression.http://www.dr-bob.org/tips/split/MAOIs-in-high-doses-and-wi.html
poster:Chairman_MAO
thread:732477
URL: http://www.dr-bob.org/babble/20070219/msgs/734846.html